Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Keith S. Reisinger"'
Autor:
Keith S. Reisinger, Jon E. Stek, Barbara J. Kuter, Julie L. Gardner, Myron J. Levin, Edgardo A. Malacaman, William Wang, Elizabeth Richardson
Publikováno v:
Vaccine. 37(38)
Objective VARIVAX® (varicella virus vaccine, live Oka/Merck, Merck & Co., Inc., Kenilworth, NJ, USA) was originally licensed as a frozen formulation. A refrigerator-stable formulation of VARIVAX was subsequently developed to allow for increased avai
Autor:
Barbara J. Kuter, Eric Shaw, Keith S. Reisinger, Katherine E.D. Giacoletti, Shelly Senders, Luwy Musey, Edgardo A. Malacaman, Florian Schödel, Jonathan Hartzel, Richard T. Wiedmann
Publikováno v:
Vaccine. 33:2132-2140
Prior to 2006, M-M-R(®)II (measles, mumps, and rubella virus vaccine live) was manufactured using human serum albumin (HSA) and each dose of the vaccine contained a relatively small amount (≤0.3mg) of HSA. Because of specific regulatory requiremen
Publikováno v:
Human Vaccines & Immunotherapeutics. 10:2395-2407
During development of an A/H1N1 pandemic influenza vaccine, this study was performed to identify the antigen and adjuvant content which would provide optimal antibody response and persistence in adults and the elderly. Dose-sparing strategies, such a
Autor:
Ching-Tien Peng, Keith S. Reisinger, Bruce L. Innis, Ignacio Salamanca de la Cueva, Vijayalakshmi Chandrasekaran, Fernando Cabañas, Shelly A. McNeil, José Garcia-Sicilia, Naresh Aggarwal, Joanne M. Langley, Varsha K. Jain, Consuelo Treviño-Garza, Archana Chatterjee, Miguel Angel Rodríguez-Weber, Li-Min Huang, Scott A. Halperin, Walthère Dewé, Manuel de la O, Alfonso Carmona Martinez, Aixue Liu
Publikováno v:
The Journal of Infectious Diseases. 208:544-553
(See the editorial commentary by Dolin on pages 539–40.) The choice of influenza virus strains to be included in each year's vaccine is a complex process in which worldwide surveillance data is used to predict the strains likely to circulate the ne
Autor:
Scott D. Patterson, Keith S. Reisinger, Douglas Girgenti, Michael W. Pride, Carmel Devlin, Kristina A. Bryant, Emilio A. Emini, Alejandra Gurtman, William C. Gruber, Anthony Johnson, Daniel A. Scott
Publikováno v:
Pediatric Infectious Disease Journal. 32:383-388
A 13-valent pneumococcal conjugate vaccine (PCV13) has been licensed in100 countries to broaden coverage against pneumococcal disease. We assessed whether PCV13 interferes with immune responses to concomitantly administered routine pediatric vaccines
Autor:
William Johnston, Tatjana Odrljin, Keith S. Reisinger, Christopher J. Gill, Nicola P. Klein, Peter M. Dull, Lisa Bedell
Publikováno v:
Pediatric Infectious Disease Journal. 31:64-71
BACKGROUND In phase II studies, MenACWY-CRM elicited robust immunologic responses in young infants. We now present results from our pivotal phase III infant immunogenicity/safety study. METHODS In this open-label phase III study, we randomized full-t
Autor:
Keith S. Reisinger, Jon E. Stek, Janie Parrino, Alexander V Murray, Jin Xu, Boris Kerzner, Paula W. Annunziato, Ivan S. F. Chan, Timothy A. Sausser, William Wang
Publikováno v:
Human Vaccines. 7:1130-1136
To evaluate the general safety of zoster vaccine (ZV) in adults ≥60 years old.Subjects were enrolled in a 1:1 ratio to receive 1 dose of ZV or placebo. Subjects were followed for serious adverse experiences (SAEs) for 42 days (primary follow-up per
Autor:
Keith S. Reisinger, Christopher J. Gill, Anil Gupta, Nicola P. Klein, Lisa Bedell, Robert Jeanfreau, Scott A. Halperin, Emmanuel B. Walter, Peter M. Dull
Publikováno v:
Vaccine. 28:7865-7872
Background Routine administration of quadrivalent meningococcal conjugate vaccine to adolescents and certain high risk groups is recommended in the United States and Canada. We compared the immunogenicity and safety of an investigational quadrivalent
Autor:
Keith S. Reisinger, Nina B Latham, Catherine Cohet, Paul-Henri Lambert, Richard M. Haupt, Paolo Bonanni, Susanne K. Kjaer
Publikováno v:
Vaccine. 28:4719-4730
GARDASIL has been shown to reduce the incidence of pre-cancerous cervical, vulvar, and vaginal lesions, and external genital warts causally related to HPV6/11/16/18. Because of its expected public health benefit on reduction of cervical cancer and ot
Publikováno v:
International Journal of Pediatric Otorhinolaryngology. 74:684-688
Objective Acute otitis media (AOM) is the most common complication of pediatric influenza, and imposes a substantial health care burden. We examined the influence of oseltamivir treatment on the incidence and course of AOM in children with influenza.